Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 8/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709666 | 0.92 | GHSR (0.43) | GHSRCCR5F2AGTR2L3MBTL1 | |
| SCHEMBL1709569 | 0.89 | GHSR (0.48) | GHSRGAAKMT2AMEN1 | |
| SCHEMBL10121719 | 0.88 | GHSR (0.48) | GHSRGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL1709728 | 0.88 | GHSR (0.43) | GHSRCCR5KMT2A | |
| SCHEMBL1709580 | 0.86 | GHSR (0.43) | GHSRCCR5AGTR2KMT2AMEN1 | |
| SCHEMBL1709686 | 0.85 | GHSR (0.45) | GHSRL3MBTL1GAAKMT2AMEN1 | |
| SCHEMBL10122142 | 0.85 | CCR5 (0.41) | GHSRCCR5F2ATMKMT2A | |
| SCHEMBL1709639 | 0.85 | GHSR (0.45) | GHSRL3MBTL1GAAKMT2AALDH1A1 | |
| SCHEMBL10122240 | 0.85 | GHSR (0.46) | GHSRGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL1709738 | 0.85 | GHSR (0.46) | GHSRCCR5F2AGTR2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | GHSR, GHRHR, STS | GHSR 1/4885CCR5 4058/4885F2 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.